Basic & clinical pharmacology & toxicology
-
Basic Clin. Pharmacol. Toxicol. · Feb 2021
Meta AnalysisPostponement of cardiovascular outcomes by statin use: A systematic review and meta-analysis of randomized clinical trials.
To estimate the average outcome postponement (gain in days to an event) for cardiovascular outcomes in a meta-analysis of randomized, controlled statin trials, including any myocardial infarction, any stroke and cardiovascular death. ⋯ Statin treatment provided a small, average postponement of cardiovascular outcomes during trial duration.
-
Basic Clin. Pharmacol. Toxicol. · Feb 2021
ReviewCamostat mesylate against SARS-CoV-2 and COVID-19-Rationale, dosing and safety.
The coronavirus responsible for COVID-19, SARS-CoV-2, utilizes a viral membrane spike protein for host cell entry. For the virus to engage in host membrane fusion, SARS-CoV-2 utilizes the human transmembrane surface protease, TMPRSS2, to cleave and activate the spike protein. Camostat mesylate, an orally available well-known serine protease inhibitor, is a potent inhibitor of TMPRSS2 and has been hypothesized as a potential antiviral drug against COVID-19. ⋯ Because camostat mesylate is administered as an oral drug, it may be used in outpatients as well as inpatients at all disease stages of SARS-CoV-2 infection if it is shown to be an effective antiviral agent. Clinical trials are currently ongoing to test whether this well-known drug could be repurposed and utilized to combat the current pandemic. In the following, we will review current knowledge on camostat mesylate mode of action, potential benefits as an antiviral agent and ongoing clinical trials.